

Bryan Oronsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4282448/publications.pdf>

Version: 2024-02-01

89
papers

2,612
citations

257357

24
h-index

214721

47
g-index

89
all docs

89
docs citations

89
times ranked

3420
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of Persistent Post-COVID Syndrome (PPCS). <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 66-74.	2.9	219
2	RRx-001 and the "Right stuff": Protection and treatment in outer space. <i>Life Sciences in Space Research</i> , 2022, 35, 69-75.	1.2	9
3	The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.. <i>American Journal of Cancer Research</i> , 2022, 12, 1912-1918.	1.4	0
4	Nucleocapsid as a next-generation COVID-19 vaccine candidate. <i>International Journal of Infectious Diseases</i> , 2022, 122, 529-530.	1.5	17
5	Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 177-183.	1.9	5
6	RRx-001, a downregulator of the CD47- SIRP1± checkpoint pathway, does not cause anemia or thrombocytopenia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 355-357.	1.5	10
7	In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. <i>Translational Lung Cancer Research</i> , 2021, 10, 274-278.	1.3	8
8	A short discussion about the SARS-CoV-2 mRNA-1273 vaccine. <i>International Journal of Infectious Diseases</i> , 2021, 104, 532-533.	1.5	3
9	RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4713.	1.8	4
10	RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 676396.	1.6	8
11	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7261-7271.	2.9	16
12	Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. <i>Journal of Drug Targeting</i> , 2021, 29, 998-1003.	2.1	8
13	Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta. <i>American Journal of Cancer Research</i> , 2021, 11, 5184-5189.	1.4	0
14	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188412.	3.3	4
15	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 305-308.	0.8	10
16	Just eat it: A review of CD47 and SIRP1± antagonism. <i>Seminars in Oncology</i> , 2020, 47, 117-124.	0.8	50
17	Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 741-742.	2.4	7
18	ARRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic". <i>Oncolmmunology</i> , 2020, 9, 1746172.	2.1	9

#	ARTICLE	IF	CITATIONS
19	Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).. Journal of Clinical Oncology, 2020, 38, e15119-e15119.	0.8	5
20	Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule of RRx-001 (001) in reducing incidence, severity and duration of severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).. Journal of Clinical Oncology, 2020, 38, 12081-12081.	0.8	1
21	RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2045-2050.	1.2	10
22	REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncology, 2019, 15, 3427-3433.	1.1	37
23	Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice. Molecular Pharmaceutics, 2019, 16, 2929-2934.	2.3	12
24	Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford Medical Case Reports, 2019, 2019, 461-463.	0.2	11
25	Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001. Biorheology, 2019, 56, 221-235.	1.2	3
26	A note on improved statistical approaches to account for pseudoprogression. Cancer Chemotherapy and Pharmacology, 2018, 81, 621-626.	1.1	4
27	A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Translational Oncology, 2018, 11, 771-778.	1.7	63
28	A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961876008.	0.3	4
29	A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. European Urology, 2018, 73, 306-307.	0.9	6
30	Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 2018, 20, 92-98.	2.3	24
31	Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. Oncotarget, 2018, 9, 23439-23442.	0.8	17
32	Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. Clinical Case Reports (discontinued), 2018, 6, 2478-2481.	0.2	0
33	A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). OncoImmunology, 2018, 7, e1478648.	2.1	10
34	Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001. Journal of Cellular and Molecular Medicine, 2018, 22, 5076-5082.	1.6	11
35	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clinical Epigenetics, 2017, 9, 4.	1.8	33
36	RRx-001 protects against cisplatin-induced toxicities. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1671-1677.	1.2	18

#	ARTICLE	IF	CITATIONS
37	The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Review of Hematology, 2017, 10, 575-582.	1.0	13
38	A brief review of the management of platinum-resistantâ€“platinum-refractory ovarian cancer. Medical Oncology, 2017, 34, 103.	1.2	125
39	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opinion on Investigational Drugs, 2017, 26, 109-119.	1.9	45
40	RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology, 2017, 10, 276-280.	0.3	6
41	What's New in SCLC? A Review. Neoplasia, 2017, 19, 842-847.	2.3	135
42	Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology, 2017, 80, 895-907.	1.1	70
43	Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia, 2017, 19, 991-1002.	2.3	474
44	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
45	Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget, 2017, 8, 102511-102520.	0.8	10
46	Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Reports in Oncology, 2016, 9, 285-289.	0.3	12
47	Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules, 2016, 6, 32.	1.8	9
48	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Medical Oncology, 2016, 33, 85.	1.2	11
49	Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases. Neuro-Oncology, 2016, 18, 455-456.	0.6	11
50	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. Translational Oncology, 2016, 9, 108-113.	1.7	28
51	Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respiratory Medicine Case Reports, 2016, 18, 62-65.	0.2	10
52	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. Medical Oncology, 2016, 33, 63.	1.2	15
53	Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology, 2016, 9, 164-170.	0.3	15
54	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S40429.	0.6	12

#	ARTICLE	IF	CITATIONS
55	RRx-001, A novel dinitroazetidide radiosensitizer. <i>Investigational New Drugs</i> , 2016, 34, 371-377.	1.2	37
56	RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. <i>Clinical Epigenetics</i> , 2016, 8, 53.	1.8	20
57	Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001. <i>Cancer Research</i> , 2016, 76, 2165-2165.	0.4	2
58	Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. <i>Oncotarget</i> , 2016, 7, 9041-9045.	0.8	5
59	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. <i>Oncotarget</i> , 2016, 7, 40781-40791.	0.8	10
60	Rockets, radiosensitizers, and RRx-001: an origin story part I. <i>Discovery Medicine</i> , 2016, 21, 173-80.	0.5	16
61	RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. <i>Discovery Medicine</i> , 2016, 21, 251-65.	0.5	16
62	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. <i>Case Reports in Oncology</i> , 2015, 8, 461-465.	0.3	13
63	The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. <i>Redox Biology</i> , 2015, 5, 422.	3.9	14
64	Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Manâ€”PFS2: A Measure of Therapeutic Action-At-A-Distance. <i>Neoplasia</i> , 2015, 17, 716-722.	2.3	21
65	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. <i>Malaria Journal</i> , 2015, 14, 218.	0.8	15
66	Going viral: a review of replication-selective oncolytic adenoviruses. <i>Oncotarget</i> , 2015, 6, 19976-19989.	0.8	110
67	The War on Cancer: A Military Perspective. <i>Frontiers in Oncology</i> , 2015, 4, 387.	1.3	15
68	NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. <i>Redox Biology</i> , 2015, 6, 1-8.	3.9	98
69	Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. <i>Asian Journal of Transfusion Science</i> , 2015, 9, 55.	0.1	15
70	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
71	Targeting Hyponitroxia in Cancer Therapy. , 2015, , 39-48.		2
72	Abstract C181: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, C181-C181.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Abstract 3515: RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy. , 2015, , .		7
74	Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Oncotarget, 2015, 6, 21547-21556.	0.8	34
75	Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget, 2015, 6, 43172-43181.	0.8	43
76	Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1121-1127.	0.9	39
77	Follow the ATP: Tumor Energy Production: A Perspective. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198.	0.9	64
78	Rewriting the Epigenetic Code for Tumor Resensitization: A Review. Translational Oncology, 2014, 7, 626-631.	1.7	37
79	Development of methods for the bioanalysis of RRx-001 and metabolites. Bioanalysis, 2014, 6, 947-956.	0.6	17
80	The Implications of Hyponitroxia in Cancer. Translational Oncology, 2014, 7, 167-173.	1.7	25
81	Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase. Cancer Research, 2014, 74, 1420-1420.	0.4	5
82	Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models. Cancer Research, 2014, 74, 2068-2068.	0.4	3
83	Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001. Blood, 2014, 124, 4712-4712.	0.6	6
84	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. PLoS ONE, 2014, 9, e101626.	1.1	28
85	Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent. Drug Metabolism and Disposition, 2012, 40, 1810-1816.	1.7	44
86	Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. Cancer Research, 2012, 72, 2600-2608.	0.4	90
87	Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. Cancer Research, 2012, 72, 4371-4371.	0.4	10
88	Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Research, 2011, 71, 676-676.	0.4	2
89	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. Blood, 2011, 118, 2125-2125.	0.6	11